4o0x
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | ==Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors== | |
- | + | <StructureSection load='4o0x' size='340' side='right' caption='[[4o0x]], [[Resolution|resolution]] 2.48Å' scene=''> | |
- | { | + | == Structural highlights == |
+ | <table><tr><td colspan='2'>[[4o0x]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4O0X OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4O0X FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2OQ:1-{[1-(4-AMINO-1,3,5-TRIAZIN-2-YL)-2-METHYL-1H-BENZIMIDAZOL-6-YL]ETHYNYL}CYCLOHEXANOL'>2OQ</scene></td></tr> | ||
+ | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=SEP:PHOSPHOSERINE'>SEP</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4o0r|4o0r]], [[4o0t|4o0t]], [[4o0v|4o0v]], [[4o0y|4o0y]]</td></tr> | ||
+ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4o0x FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4o0x OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4o0x RCSB], [http://www.ebi.ac.uk/pdbsum/4o0x PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Structure-based methods were used to design a potent and highly selective group II p21-activated kinase (PAK) inhibitor with a novel binding mode, compound 17. Hydrophobic interactions within a lipophilic pocket past the methionine gatekeeper of group II PAKs approached by these type I 1/2 binders were found to be important for improving potency. A structure-based hypothesis and strategy for achieving selectivity over group I PAKs, and the broad kinome, based on unique flexibility of this lipophilic pocket, is presented. A concentration-dependent decrease in tumor cell migration and invasion in two triple-negative breast cancer cell lines was observed with compound 17. | ||
- | + | Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors.,Staben ST, Feng JA, Lyle K, Belvin M, Boggs J, Burch JD, Chua CC, Cui H, Dipasquale AG, Friedman LS, Heise C, Koeppen H, Kotey A, Mintzer R, Oh A, Roberts DA, Rouge L, Rudolph J, Tam C, Wang W, Xiao Y, Young A, Zhang Y, Hoeflich KP J Med Chem. 2014 Feb 4. PMID:24432870<ref>PMID:24432870</ref> | |
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | == | + | ==See Also== |
- | + | *[[Serine/threonine protein kinase|Serine/threonine protein kinase]] | |
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
[[Category: Non-specific serine/threonine protein kinase]] | [[Category: Non-specific serine/threonine protein kinase]] | ||
- | [[Category: Rouge,L.]] | + | [[Category: Rouge, L.]] |
[[Category: Tam, C.]] | [[Category: Tam, C.]] | ||
[[Category: Wang, W.]] | [[Category: Wang, W.]] | ||
[[Category: Pak4]] | [[Category: Pak4]] | ||
[[Category: Transferase-transferase inhibitor complex]] | [[Category: Transferase-transferase inhibitor complex]] |
Revision as of 06:54, 5 November 2014
Back pocket flexibility provides group-II PAK selectivity for type 1 kinase inhibitors
|